Merck & Co., (MRK) and Daiichi Sankyo Announces Positive Results for Ifinatamab deruxtecan

Merck & Co., Inc. (NYSE:MRK) is one of the Blue Chip Stocks to Buy with the Lowest PE Ratios. On September 7, Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced positive Phase 2 results for Ifinatamab deruxtecan in treating extensive-stage small cell lung cancer.

The trial showed a confirmed objective response rate of 48.2% in 137 previously treated ES-SCLC patients. Management noted that 3 complete responses, 63 partial responses, and 54 cases of stable disease were seen. Moreover, the disease control rate was 87.6% with a median duration of response being 5.3 months and a median overall survival of 10.3 months.

The drug under trial is a potential first-in-class B7-H3-directed antibody-drug conjugate, which is being jointly developed by Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo. ES-SCLC is an aggressive cancer with a poor prognosis and limited treatment options after chemotherapy.

Merck & Co., Inc. (NYSE:MRK) is a global healthcare company focused on developing and delivering prescription medicines, vaccines, and animal health products.

While we acknowledge the potential of MRK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than MRK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.